Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O95971

UPID:
BY55_HUMAN

ALTERNATIVE NAMES:
Natural killer cell receptor BY55

ALTERNATIVE UPACC:
O95971; A0A0B4J2A1; B8PRF2; Q5T2V6

BACKGROUND:
CD160 antigen, identified as Natural killer cell receptor BY55, is crucial for immune cell signaling. It binds to MHC class I molecules, playing a significant role in the immune system's response to viral infections and in T cell exhaustion during chronic viral infections. Additionally, CD160's interaction with TNFRSF14 modulates immune responses, suggesting its involvement in both stimulatory and inhibitory pathways in immune regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of CD160 antigen offers promising avenues for therapeutic intervention. Its critical role in modulating immune responses, particularly in the context of viral infections and cancer, underscores its potential as a novel target for immunotherapy and drug development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.